Biosimilar Matches Keytruda Response in Lung Cancer
Patients with metastatic lung cancer may eventually have a lower-cost immunotherapy option after a Phase 3 trial.
Updated on Nov. 6, 2026 in Cancer

Samsung Bioepis presented Phase 3 findings for SB27, a proposed biosimilar to Keytruda (pembrolizumab), at the SITC 2026 meeting in Phoenix, Arizona. The trial found response rates comparable to the reference drug in patients with metastatic non-squamous non-small cell lung cancer receiving first-line chemotherapy.
Why it matters
Biosimilars aim to offer lower-cost alternatives to expensive biologic cancer drugs, which could widen access to immunotherapy for people with lung cancer if approved. The study's equivalence design was built to show the proposed version performs in line with the original rather than merely similar on average.
This Phase 3 randomized, double-blind, multicenter trial enrolled 555 patients with metastatic non-squamous NSCLC, split 1:1 between SB27 and reference pembrolizumab. The primary endpoint, objective response rate at Week 24, was 34.6% versus 37.9%, and the confidence interval sat entirely within the pre-set equivalence margin.
The players
Samsung Bioepis
The biosimilar developer, a division of Samsung Biologics, that develops lower-cost versions of biologic medicines including oncology antibodies.
Keytruda
Merck's brand of pembrolizumab, a PD-1 immune checkpoint inhibitor widely used across multiple cancer types.
SITC
The Society for Immunotherapy of Cancer, which hosts an annual meeting presenting immuno-oncology research.
The details
Pembrolizumab is a humanized monoclonal antibody that blocks the PD-1 receptor on T cells, releasing the immune system's ability to attack tumor cells. Participants in the trial received 200 mg intravenously every three weeks alongside pemetrexed and carboplatin for the first four cycles. The study also compared safety, pharmacokinetics, and immunogenicity, and the researchers reported these profiles were comparable to Keytruda.
Timeline
November 4 to 8, 2026: SITC Annual Meeting 2026 held in Phoenix, Arizona.
November 6, 2026: Samsung Bioepis announced the Phase 3 SB27 findings.
Week 24: Primary endpoint response rate measured for trial participants.
Health Landscape
Pembrolizumab became one of the most widely used immunotherapies after its initial approval, with its use expanding across many solid tumors, which made it a major cost driver in oncology. Biosimilar entrants such as SB27 are being tested against that reference standard to see whether they can offer comparable efficacy at lower cost.
If you or a family member are being evaluated for lung cancer, this research is worth raising with your oncologist as biosimilar options develop over time. Any decision about switching to a biosimilar version of an immunotherapy should be made with your care team, who can weigh availability and coverage.
The takeaway
A Phase 3 result showing comparable response rates is an early step toward more affordable immunotherapy for lung cancer. Patients interested in treatment options should ask their oncologist which therapies are currently approved and covered in their area.
Further reading
For background on how these treatments are tested and used, explore our Cancer coverage.


